Cellular signalling of adrenomedullin regulating endothelial barrier function and granulocyte extravasation

Q. Mao
2012-11-11
Abstract:Background: Disturbed endothelial barrier function is a hallmark of inflammation. Effusion of protein rich plasma fluid leading to edema formation and overshooting transmigration of leukocytes contribute to severe organ dysfunction under conditions of generalized inflammation, e.g. acute lung injury and sepsis. The peptide hormone Adrenomedullin (ADM) and its receptor (CRLR/RAMP2/3) constitute an important signaling system for the protection of endothelial barrier function. Although elevation of cAMP in endothelial cells was identified as signaling pathway of ADM responsible for barrier protection, it was speculated that other mechanisms are involved and precise intracellular signaling routes have not been explored, yet. Main findings and conclusions: ADM was confirmed to be a strong stabilizer of the endothelial barrier function in vitro, preventing and reversing hyperpermeability independent of the inflammatory stimulus (as determined by electrical impedance and FITC-dextran permeability measurements after stimulation with thrombin, TNFα, histamine, VEGF). Moreover, it was shown for the first time that ADM inhibited TNFα-induced granulocyte transmigration which was solely due to effects of ADM on endothelial cells. These in vitro-findings could be translated to animal models of vascular permeability and inflammation: ADM dose-dependently reduced vascular permeability in the skin of mice and rats (Miles assay; stimulus histamine). In a murine lipopolysaccharide (LPS)-induced lung injury model, ADM reduced lung edema and leukocyte extravasation. In endothelial cells, barrier protection could solely be reduced to cAMP signaling via the protein kinase A (PKA) and Epac-Rap1 pathways (dose response comparison with Forskolin). Dissection of the downstream cascade by means of cAMP analogs, specific for PKA and Epac-Rap1 signaling (benz-cAMP and “007”, respectively), demonstrated that both pathways are with respect to their efficacy equally involved in effects on permeability probably addressing independent effector mechanisms as suggested by enhanced efficacy of combination of both. Consistently, both pathway activators prevented vascular hyper-permeability in vivo. PKA activation and inhibition of MLC phosphorylation downstream of ADM diminish stimulus induced actin stressfiber formation and contraction of endothelial cells thus counteracting intercellular gap formation and hyperpermeability. Most notably, also effects independent of the contractile apparatus were demonstrated: ADM stabilized barrier function even in the absence of a functional actin cytosceletton after treatment with Cytochalasin D and knockdown of cortactin. ADM induced stabilization of VE-cadherin at the cell borders and increased the amount of detectable VE-cadherin/VE-PTP complex which is important for the regular function of VE-cadherin. In contrast, granulocyte transmigration was only reduced by PKA activation and ADM effects were lost after knockdown of cortactin. In line with this finding, a PKA inhibitor abolished the effect of ADM. As PKA activation reduces myosin light chain phosphorylation these data collectively link leukocyte extravasation to the contractile apparatus of the endothelial cell. As “007” was fully active with respect to TNFα induced hyperpermeability but had no effect with respect to granulocyte transmigration, endothelial hyperpermeability per se is not a prerequisite for granulocyte transmigration.
Medicine,Biology
What problem does this paper attempt to address?